ADVERTISEMENTs
Bexion Pharma names Dr Tariq Arshad as chief medical officer
Dr Arshad said, “I am eager to drive the clinical programs forward and develop a potential first-in-class product that could help the vast number of patients currently lacking effective treatments."
Dr Tariq Arshad / Image: LinkedIn
Covington, Kentucky-based Bexion Pharmaceuticals Inc. has named Dr Tariq Arshad as its chief medical officer.
An oncologist with more than 25 years of experience Arshad is also experienced in strategic planning, clinical development, and commercialization.
He previously served as the chief medical officer and head of research and development (R&D) at Qualigen Therapeutics in Carlsbad, California, where he played a crucial role in advancing the company's lead asset QN-302 as well as its Pan-RAS portfolio.
According to his bio, Arshad has led medical strategies for successful biologic therapies approved for clinical use in major immunology indications and other therapies as head of medical affairs for immunology at Sanofi Genzyme.
Additionally, as chief medical officer and head of clinical research at Humanigen, he contributed to the development of novel immune-oncology therapies.
Commenting on the appointment, the company's chief executive officer, Scott Shively, said, "We are thrilled to appoint Dr Arshad as Bexion's chief medical officer. With over 25 years in the biotechnology and pharmaceutical industry, Dr Arshad's immense experience will greatly benefit our team as we move forward with our mCRC and CIPN clinical programs. We are eager to leverage his extensive skill set and welcome him on board."
Reacting to the appointment, Arshad said, "This is a very exciting time to join Bexion with the evaluation of BXQ-350 for the treatment of mCRC and CIPN firmly in the clinic. I am eager to drive the clinical programs forward and develop a potential first-in-class product that could help the vast number of patients currently lacking effective treatments."
Arshad actively participates in professional societies such as the American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR), and Society for Immunotherapy of Cancer (SITC). He completed his MD in medicine and surgery from the University of Punjab, India, and a master’s in public and global health from Yale University School of Medicine, and another master's in business administration and healthcare from the George Washington University School of Business.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
.jpg)
E Paper
ADVERTISEMENT
Video
.jpg)
.png)
.png)
.png)
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login